人表皮生长因子受体2低表达乳腺癌的研究进展及挑战  

Progress and challenges of human epidermal growth factor receptor 2-low expressing breast cancer

作　　者：李雪 韩萌萌 冯雪园 马宁[1] Li Xue;Han Mengmeng;Feng Xueyuan;Ma Ning(Department of Breast Surgery,Baoding No.1 Central Hospital,Hebei Medical University,Baoding 071000,China)

机构地区：[1]河北省保定市第一中心医院乳腺外科,071000

出　　处：《中华普通外科学文献（电子版）》2024年第4期308-312,共5页Chinese Archives of General Surgery(Electronic Edition)

摘　　要：乳腺癌是女性最常见的恶性肿瘤,极大威胁女性身体健康。人表皮生长因子受体2(HER-2)是乳腺癌治疗的重要靶点,针对HER-2阳性乳腺癌靶向治疗的研究已经非常广泛,而HER-2低表达以往被归为阴性乳腺癌,较少能从传统的抗HER-2治疗中获益。但随着抗体偶联药物在HER-2低表达乳腺癌中疗效的确立,使得HER-2低表达成为新的乳腺癌治疗亚型。本文将对HER-2低表达乳腺癌的定义、临床病理特征和预后意义、治疗进展等方面进行总结阐述。Breast cancer is the most frequently diagnosed cancer in women,which poses a great threat to women’s health.Human epidermal growth factor receptor 2(HER-2)is an important target for the treatment of breast cancer,and targeted therapy for HER-2-positive breast cancer has been widely studied.HER-2 low expression was previously classified as negative breast cancer and rarely or could not benefit from traditional anti-HER-2 therapy.However,with the established efficacy of antibody-drug conjugates,HER-2-low expressing breast cancer has become a new subtype for treatment.This article will summarize the definition,clinicopathological features,prognosis and treatment progress of HER-2-low expressing breast cancer.

关 键 词：人表皮生长因子受体2 低表达 乳腺肿瘤 检测标准 临床病理特征 治疗进展 

分 类 号：R737.9[医药卫生—肿瘤]